演題概要

オーラルセッション

第1日　5月15日（水）　16:05～16:25　C会場（101）

1C-O1-1605　　PDF

核酸医薬の定量について考える：MS法の適用についてJBF DGでの議論の紹介

(¹シミックファーマサイエンス・ ²LSIメディエンス・ ³大日本住友製薬・ ⁴アステラス製薬・ ⁵塩野義製薬・ ⁶協和発酵キリン・ ⁷田辺三菱製薬・ ⁸大塚製薬・ ⁹グラクソ・スミスクライン)
^o林善治¹・ 新井浩司²・ 石川千裕³・ 大崎史雄⁴・ 鎌倉健雄⁵・ 戸嶋麻美⁶・ 安原秀典⁷・ 横井宏之⁸・ 若松明⁹

Japan Bioanalysis Forum (JBF) handles “Discussion Group (DG)” which discusses some issues or questions about bioanalysis in closed with small scale group. Our group (DG36) presented about the topic of “Quantitative analysis of oligonucleotide therapeutics by LC-MS”. The group consisted of nine members. They focused on five themes in which DG members were interested; “sample preparation”, “instrument”, “internal standard”, “validation”, and “comparison with ligand binding assay” and presented an overview of their discussion. Moreover they surveyed the current situation about the quantification of oligonucleotide therapeutics using LC-MS and the results were shared. In this presentation, I will introduce the essence of our report presented in 10th JBF Symposium (held on February 12 - 14, 2019).